Introduction
Lafora disease (LD; OMIM 254780), one of the genetic progressive myoclonus epilepsies (PME), is a fatal autosomal recessive disorder. LD is characterized by periodic acid-Schiff positive (PAS+) staining intracellular inclusion bodies, which are pathognomic of the disease.
Symptoms of LD are expressed in early adolescence and include generalized, mostly stimulus-sensitive, tonic-clonic and myoclonic seizures as well as absences. Progressive dementia, psychosis, cerebellar ataxia, dysarthria, amaurosis, mutism, muscle wasting and respiratory failure develop later and lead to death usually within a decade of the symptoms' onset.
The genetic basis of LD is attributed to two different genes. The EPM2A gene is located on chromosome 6q24 1 and encodes laforin, while the EPM2B gene located on chromosome 6p22 encodes for malin, an E3 ubiquitin ligase.
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The disease is treated symptomatically as there is no preventive treatment or cure.
Case study
Our report shall refer to the case of a young girl with no apparent symptoms of neurological disease until the age of 13. At that age, she manifested absence seizures (brief starring spells) and visual auras with colorful flashes lasting a few seconds. Seizures' frequency was no more than 1-2/week and they were triggered during eating or while watching TV or other flashing lights. A few months later, she developed generalized tonic-clonic seizures. During the same time, a decline in her school performance was evident along with generalized shortfall in her cognitive function. She was treated with valproic acid, but it failed to control seizures adequately. Two years later, myoclonic seizures were added to her clinical manifestations and soon evolved as the most prominent seizure type. Her cognitive decline was advancing so fast, that the patient had to drop out of school 3 years after the onset of the symptoms. All known antiepileptic drugs were tried in different combinations but none was to prove effective.
Today, she is 24 years old and suffers from repeated myoclonic seizures, which are triggered by every possible stimulus (visual, auditory, tactile or through her being moved). Her cognitive decline is so severe that the patient has lost the ability to communicate verbally and she can pronounce some words with great difficulty, in an incomprehensible, dysarthric way. Her parents claim that the patient can still recognize members of her family, as can be inferred by her emotional responses. She is heavily disabled, suffering severe tetraparesis with no ability to stand on her own. She has lost control of her sphincters, is bedridden and totally dependent.
The patient's ECG has been abnormal since the manifestation of her symptoms. The most recent ECG showed a total absence of a well-organized alpha rhythm. Regarding non-epileptiform findings, diffuse theta and delta waves were evident while epileptiform activity was characterized by generalized spike-wave complexes, coinciding with photosensitivity.
An MRI brain scan, conducted during the onset of the symptoms, was normal. Another one, performed one year later, revealed bilateral Ammon's horn sclerosis and excessive brain atrophy.
Myoclonic epilepsy was considered a possible diagnosis and a skin biopsy was performed, yielding no obvious histopathological findings. The diagnosis was established at the age of 19 by gene sequencing, which identified an homozygous mutation in the EPM2A gene. Analysis was performed by PCR amplification of genomic DNA, followed by automated uni-directional DNA sequencing of the entire coding region, including the highly conserved flanking intronic sequences of the exon-intron splice junctions for all coding exons.
The patient is homozygous for a nonsense G > A mutation at nucleotide 861 of the EPM2A gene. This mutation causes an aminoacid substitution at position 287 of the laforin protein. Tryptophan is replaced by a stop codon, resulting in a truncated protein, potentially responsible for the clinical presentation of epilepsy in our patient.
Three years after the initiation of the patient's seizures and while no diagnosis had been made, her older brother and her only sibling in the family, developed the same symptomatology at the age of 17. His deterioration was much more accelerated with frequent episodes of status epilepticus (SE). During an episode of SE, two years after his symptoms' onset, he died. Unfortunately, no gene analysis had been sent before his death, although it was quite clear that the two siblings had been suffering from the same disease.
Both parents, presumed carriers of the mutation, originate from an area with an isolated population in Northwest Greece, imposing an increased risk for consanguinity. Unfortunately, their consent for gene analysis has not been granted and the presence of the mutation in their DNA samples cannot be confirmed.
To our knowledge, this is a new mutation associated with the Lafora disease, further expanding the range of identified mutations and providing new insights into the genotype-phenotype association for this disease.
Discussion
In the above described case, a new mutation in the EPM2A gene found in Northwest Greece is causing an amino-acid substitution at position 287 of the laforin protein (Fig. 1) . More specifically, tryptophan is replaced by a stop codon, resulting in a truncated protein, potentially responsible for the clinical presentation of epilepsy in our patient.
Laforin is a dual-specificity protein phosphatase, encoded by the EPM2A gene, which is composed of 4 exons. 3 The N-terminal carbohydrate binding domain (CBD) is encoded mainly by exon 1, while the dual-specificity phosphatase domain (DSPD) by exons 3 and 4. 4 Laforin interacts with malin, a ubiquitin ligase protein encoded by the EPM2B gene located on chromosome 6p22. Malin polyubiquitinates laforin leading to its degradation. 5 The EPM2A gene, located on chromosome 6q24, has been associated with a wide spectrum of mutations. A recent metaanalysis presented a list of 100 distinct mutations. 6 Missense and nonsense mutations are responsible for 60% of point mutations of the EPM2A gene, while insertion mutations account for 13% of the total. Deletion mutations are also common in the EPM2A gene, with 23 families reported to have large deletions. One third of the total known mutations are clustered in exon 1, while the presence of mutations is lower in exons 2 and 3. Exons 1 and 4 encode the functional domains of laforin and mutations in these regions can have a critical impact on laforin's functionality. Our novel mutation is located at nucleotide 861, which is located on exon 4 and leads to a stop codon near the DSPD region. The function of the laforin-malin complex is not clearly understood and many different theories have been proposed. As glycogen is a branched glucose polymer containing small amounts of phosphate, the lack of laforin's dephosphorylation activity may lead to increases in phosphate content, causing abnormal branching, which subsequently results in insoluble Lafora bodies formation. A recent study 7 reported a 40% increase of glycogen phosphate content in liver and a 4-fold elevation in muscle using an Epm2aÀ/À mouse model. Still, other pathophysiologic pathways may be implicated in the Lafora disease occurrence. Currently, evidence supports a critical role of the laforin-malin complex in cellular protein clearance. 8 A recent study revealed the presence of enlarged lysosomes, lipofuscin granules, amyloid bpeptides and insoluble ubiquitinated protein, in a laforin-deficient mice model, supporting the hypothesis of cellular degradative pathway impairment. 9 Furthermore, it has been shown that lack of laforin in an EPM2A knockout mice model suggests a cooperative role for the laforin-malin complex in relieving endoplasmic reticulum stress and cell apoptosis. 10 Lafora bodies can be found in neurons, skin, bone, muscles and internal organs, such as the liver. They can be detected in skin biopsies using PAS+ or Alcian blue staining. Skin biopsy remains a widely used method for diagnosis due to its convenience, low cost and minimal invasiveness. Still, there are some drawbacks, as the absence of Lafora inclusion bodies cannot exclude the diagnosis. This makes genetic confirmation necessary for a conclusive diagnosis.
Although Lafora bodies are a hallmark of the disease, data seem to support that they are not a causal factor of neuronal degeneration and epileptogenesis, but the consequence of defects in the same physiological pathway which leads to epileptic seizures, as reported in a study of the EPM2A gene knocked mice. 3 However, using a similar Epm2aÀ/À mouse model, a recent study 7 has reported increases in glycogen phosphate content in liver and muscles resulting in impaired glycogen branching and insoluble particle formation. Authors support that as phosphate overaccumulation in glycogen may be a slow process, this may explain the late onset of symptoms in Lafora disease.
Conclusion
Herein, we present a new mutation near the DSPD region of laforin protein in a homozygosity state causing the Lafora disease phenotype. Although the detection of Lafora bodies is widely used, genetic analysis may more decisive in diagnosis confirmation and further explores genotype-phenotype interactions in novel mutations.
